Cargando…

Novel mutations in NSP-1 and PLPro of SARS-CoV-2 NIB-1 genome mount for effective therapeutics

BACKGROUND: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the etiologic agent of coronavirus disease 2019 (COVID-19), is rapidly acquiring new mutations. Analysis of these mutations is necessary for gaining knowledge regarding different aspects of therapeutic development. Previously,...

Descripción completa

Detalles Bibliográficos
Autores principales: Hossain, Mohammad Uzzal, Bhattacharjee, Arittra, Emon, Md. Tabassum Hossain, Chowdhury, Zeshan Mahmud, Ahammad, Ishtiaque, Mosaib, Md. Golam, Moniruzzaman, Md., Rahman, Md. Hadisur, Islam, Md. Nazrul, Ahmed, Irfan, Amin, Md. Ruhul, Rashed, Asif, Das, Keshob Chandra, Keya, Chaman Ara, Salimullah, Md.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017899/
https://www.ncbi.nlm.nih.gov/pubmed/33797663
http://dx.doi.org/10.1186/s43141-021-00152-z
_version_ 1783674138928349184
author Hossain, Mohammad Uzzal
Bhattacharjee, Arittra
Emon, Md. Tabassum Hossain
Chowdhury, Zeshan Mahmud
Ahammad, Ishtiaque
Mosaib, Md. Golam
Moniruzzaman, Md.
Rahman, Md. Hadisur
Islam, Md. Nazrul
Ahmed, Irfan
Amin, Md. Ruhul
Rashed, Asif
Das, Keshob Chandra
Keya, Chaman Ara
Salimullah, Md.
author_facet Hossain, Mohammad Uzzal
Bhattacharjee, Arittra
Emon, Md. Tabassum Hossain
Chowdhury, Zeshan Mahmud
Ahammad, Ishtiaque
Mosaib, Md. Golam
Moniruzzaman, Md.
Rahman, Md. Hadisur
Islam, Md. Nazrul
Ahmed, Irfan
Amin, Md. Ruhul
Rashed, Asif
Das, Keshob Chandra
Keya, Chaman Ara
Salimullah, Md.
author_sort Hossain, Mohammad Uzzal
collection PubMed
description BACKGROUND: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the etiologic agent of coronavirus disease 2019 (COVID-19), is rapidly acquiring new mutations. Analysis of these mutations is necessary for gaining knowledge regarding different aspects of therapeutic development. Previously, we have reported a Sanger method-based genome sequence of a viral isolate named SARS-CoV-2 NIB-1, circulating in Bangladesh. The genome has four novel non-synonymous mutations in V121D, V843F, A889V, and G1691C positions. RESULTS: Using different computational tools, we have found V121D substitution has the potential to destabilize the non-structural protein-1 (NSP-1). NSP-1 inactivates the type-1 interferon-induced antiviral system. Hence, this mutant could be a basis of attenuated vaccines against SARS-CoV-2. V843F, A889V, and G1691C are all located in nonstructural protein-3 (NSP-3). G1691C can decrease the flexibility of the protein. V843F and A889V might change the binding pattern and efficacy of SARS-CoV-2 papain-like protease (PLPro) inhibitor GRL0617. V843F substitution in PLPro was the most prevalent mutation in the clinical samples. This mutation showed a reduced affinity for interferon-stimulated gene-15 protein (ISG-15) and might have an impact on innate immunity and viral spread. However, V843F+A889V double mutant exhibited the same binding affinity as wild type PLPro. A possible reason behind this phenomenon can be that V843F is a conserved residue of PLPro which damaged the protease structure, but A889V, a less conserved residue, presumably neutralized that damage. CONCLUSIONS: Mutants of NSP-1 could provide attenuated vaccines against coronavirus. Also, these mutations of PLPro might be targeted to develop better anti-SARS therapeutics. We hope our study will help to get better insides during the development of attenuated vaccine and PLPro inhibitors. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s43141-021-00152-z.
format Online
Article
Text
id pubmed-8017899
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-80178992021-04-06 Novel mutations in NSP-1 and PLPro of SARS-CoV-2 NIB-1 genome mount for effective therapeutics Hossain, Mohammad Uzzal Bhattacharjee, Arittra Emon, Md. Tabassum Hossain Chowdhury, Zeshan Mahmud Ahammad, Ishtiaque Mosaib, Md. Golam Moniruzzaman, Md. Rahman, Md. Hadisur Islam, Md. Nazrul Ahmed, Irfan Amin, Md. Ruhul Rashed, Asif Das, Keshob Chandra Keya, Chaman Ara Salimullah, Md. J Genet Eng Biotechnol Research BACKGROUND: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the etiologic agent of coronavirus disease 2019 (COVID-19), is rapidly acquiring new mutations. Analysis of these mutations is necessary for gaining knowledge regarding different aspects of therapeutic development. Previously, we have reported a Sanger method-based genome sequence of a viral isolate named SARS-CoV-2 NIB-1, circulating in Bangladesh. The genome has four novel non-synonymous mutations in V121D, V843F, A889V, and G1691C positions. RESULTS: Using different computational tools, we have found V121D substitution has the potential to destabilize the non-structural protein-1 (NSP-1). NSP-1 inactivates the type-1 interferon-induced antiviral system. Hence, this mutant could be a basis of attenuated vaccines against SARS-CoV-2. V843F, A889V, and G1691C are all located in nonstructural protein-3 (NSP-3). G1691C can decrease the flexibility of the protein. V843F and A889V might change the binding pattern and efficacy of SARS-CoV-2 papain-like protease (PLPro) inhibitor GRL0617. V843F substitution in PLPro was the most prevalent mutation in the clinical samples. This mutation showed a reduced affinity for interferon-stimulated gene-15 protein (ISG-15) and might have an impact on innate immunity and viral spread. However, V843F+A889V double mutant exhibited the same binding affinity as wild type PLPro. A possible reason behind this phenomenon can be that V843F is a conserved residue of PLPro which damaged the protease structure, but A889V, a less conserved residue, presumably neutralized that damage. CONCLUSIONS: Mutants of NSP-1 could provide attenuated vaccines against coronavirus. Also, these mutations of PLPro might be targeted to develop better anti-SARS therapeutics. We hope our study will help to get better insides during the development of attenuated vaccine and PLPro inhibitors. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s43141-021-00152-z. Springer Berlin Heidelberg 2021-04-02 /pmc/articles/PMC8017899/ /pubmed/33797663 http://dx.doi.org/10.1186/s43141-021-00152-z Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Research
Hossain, Mohammad Uzzal
Bhattacharjee, Arittra
Emon, Md. Tabassum Hossain
Chowdhury, Zeshan Mahmud
Ahammad, Ishtiaque
Mosaib, Md. Golam
Moniruzzaman, Md.
Rahman, Md. Hadisur
Islam, Md. Nazrul
Ahmed, Irfan
Amin, Md. Ruhul
Rashed, Asif
Das, Keshob Chandra
Keya, Chaman Ara
Salimullah, Md.
Novel mutations in NSP-1 and PLPro of SARS-CoV-2 NIB-1 genome mount for effective therapeutics
title Novel mutations in NSP-1 and PLPro of SARS-CoV-2 NIB-1 genome mount for effective therapeutics
title_full Novel mutations in NSP-1 and PLPro of SARS-CoV-2 NIB-1 genome mount for effective therapeutics
title_fullStr Novel mutations in NSP-1 and PLPro of SARS-CoV-2 NIB-1 genome mount for effective therapeutics
title_full_unstemmed Novel mutations in NSP-1 and PLPro of SARS-CoV-2 NIB-1 genome mount for effective therapeutics
title_short Novel mutations in NSP-1 and PLPro of SARS-CoV-2 NIB-1 genome mount for effective therapeutics
title_sort novel mutations in nsp-1 and plpro of sars-cov-2 nib-1 genome mount for effective therapeutics
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017899/
https://www.ncbi.nlm.nih.gov/pubmed/33797663
http://dx.doi.org/10.1186/s43141-021-00152-z
work_keys_str_mv AT hossainmohammaduzzal novelmutationsinnsp1andplproofsarscov2nib1genomemountforeffectivetherapeutics
AT bhattacharjeearittra novelmutationsinnsp1andplproofsarscov2nib1genomemountforeffectivetherapeutics
AT emonmdtabassumhossain novelmutationsinnsp1andplproofsarscov2nib1genomemountforeffectivetherapeutics
AT chowdhuryzeshanmahmud novelmutationsinnsp1andplproofsarscov2nib1genomemountforeffectivetherapeutics
AT ahammadishtiaque novelmutationsinnsp1andplproofsarscov2nib1genomemountforeffectivetherapeutics
AT mosaibmdgolam novelmutationsinnsp1andplproofsarscov2nib1genomemountforeffectivetherapeutics
AT moniruzzamanmd novelmutationsinnsp1andplproofsarscov2nib1genomemountforeffectivetherapeutics
AT rahmanmdhadisur novelmutationsinnsp1andplproofsarscov2nib1genomemountforeffectivetherapeutics
AT islammdnazrul novelmutationsinnsp1andplproofsarscov2nib1genomemountforeffectivetherapeutics
AT ahmedirfan novelmutationsinnsp1andplproofsarscov2nib1genomemountforeffectivetherapeutics
AT aminmdruhul novelmutationsinnsp1andplproofsarscov2nib1genomemountforeffectivetherapeutics
AT rashedasif novelmutationsinnsp1andplproofsarscov2nib1genomemountforeffectivetherapeutics
AT daskeshobchandra novelmutationsinnsp1andplproofsarscov2nib1genomemountforeffectivetherapeutics
AT keyachamanara novelmutationsinnsp1andplproofsarscov2nib1genomemountforeffectivetherapeutics
AT salimullahmd novelmutationsinnsp1andplproofsarscov2nib1genomemountforeffectivetherapeutics